Is BPC-157 Legal in Florida? How to Access It Legally

What is BPC-157's legal status?

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice [1]. No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing BPC-157 in any country it searched [1].

BPC-157 is also on neither of FDA's lists of nominated bulk substances: it is in none of the three categories on the list for state-licensed pharmacies and physicians [2], and it is not on the list for outsourcing facilities, the large registered compounders [7].

Where do Florida laws come in?

Florida's pharmacy practice law is Chapter 465 of the Florida Statutes, covering pharmacy permits, practice standards and disciplinary action [5]. Grounds for disciplinary action against a physician are listed in section 458.331 [6]. The federal documents on BPC-157 are written around state-licensed pharmacies and licensed physicians, so for a Florida pharmacy the question the facts address is whether its BPC-157 compounding falls inside the enforcement discretion described in the HHS draft [3].

How the compounding status changed, 2023 to 2026

• September 2023 to April 22, 2026: BPC-157 sat in FDA's category 2, the nominated substances FDA said may present significant safety risks [10].
• April 22, 2026: it moved to a separate 'nominated but withdrawn' table because the groups that nominated it withdrew. Removal from category 2 was not a finding of safety [10].
• May 14, 2026: on FDA's list of nominated substances for state-licensed pharmacies and physicians, BPC-157 sits in none of the three categories, so category 1 (the group FDA says it generally will not act against compounders for, if conditions are met) does not cover it [2].
• July 2026: FDA's own reviewers recommended against adding BPC-157 to the pharmacy bulk list, citing poor chemical characterization, limited safety and immunogenicity information, insufficient evidence that it works for ulcerative colitis, and several approved drugs that already treat that condition [1].
• July 23, 2026: FDA's Pharmacy Compounding Advisory Committee voted in favor of adding it, against staff's recommendation; news reports give the vote as 8 to 6 with 1 abstention. The vote is advice only. BPC-157 is not on the list, and adding it requires formal rulemaking [3][11].
• October 28, 2026: HHS filed notice of a draft enforcement-discretion policy covering six peptides, BPC-157 among them [3].

What the draft HHS policy actually says

The notice is scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication. It says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA develops its list through rulemaking, if the policy's conditions are met [3].

For BPC-157, the draft lists these conditions for that stated enforcement discretion [4]:

• BPC-157 acetate only
• subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous are not listed
• a single active ingredient
• bulk substance from an FDA-registered manufacturer, with a valid certificate of analysis meeting a peptide testing standard
• a patient-specific prescription
• a label reading 'This is a compounded drug product. Not for resale.'
• serious adverse events and quality problems reported to FDA MedWatch
• only an FDA 510(k)-cleared syringe as a co-packaged device
• documentation of adequate bioavailability for oral forms

Three limits matter. The notice states the policy 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example after a safety signal or a product quality problem [3]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [3][7]. And compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [3].

What about the sellers shipping to Florida?

FDA has noted websites selling BPC-157, alone or blended with TB-500, as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use'. Those products are not FDA-approved drugs [1]. FDA's stated concerns about compounded BPC-157 are immunogenicity risk for certain routes of administration, peptide-related impurities, difficulty characterizing the active ingredient, and 'no, or only limited, safety-related information' for the proposed routes [10].

What is known about safety and effectiveness?

Human data are thin. FDA's search of its adverse-event database through December 4, 2025 turned up 3 reports, all injectable BPC-157: injection-site redness and swelling lasting 9 days, shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 product. FDA said it cannot tell whether BPC-157 caused them, and concluded there is 'insufficient clinical safety information to characterize the safety profile' [1].

In 28-day intramuscular animal studies, BPC-157 shortened clotting time in rats and prolonged it in dogs, and raised liver enzyme, glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1]. FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or skin use [1].

The human studies are small. A chart review at one Florida clinic covered 17 patients with knee pain, 12 of them given BPC-157 alone, and 11 of those 12 reported significant improvement; there was no control group and no validated outcome tool [12]. A single-arm pilot gave 12 women with interstitial cystitis who had not responded to pentosan polysulfate 10 mg injected around the bladder wall, and 10 reported complete symptom resolution [13]. A third study gave 2 adults 10 mg and then 20 mg intravenously on two days and reported no measurable change in the tested markers and no side effects; with 2 people, it cannot establish safety [14]. A 53-person trial of an 80 mg enema versus placebo for two weeks in ulcerative colitis was reported only at a conference, and FDA said it had too little detail to judge effectiveness [1]. A 2026 systematic review found only 3 studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low, and concluded BPC-157 should not be used clinically outside approved, regulated, high-quality trials [9].

Is BPC-157 allowed in competitive sport?

No. WADA's Prohibited List names BPC-157 in S0, non-approved substances, and it is prohibited at all times, in and out of competition; the 2026 List has been in force since January 1, 2026 [8]. BPC-157 was first named as an S0 example in the 2022 List and remains named in the 2027 List [15][16].

What happens next

Adding BPC-157 to the pharmacy bulk list would require a proposed rule, public comment and a final rule [3]. The HHS draft is open for public comment for two weeks after its Federal Register publication [3].